Cardiac Hypertrophy: The Good, the Bad, and the Ugly

Annual Review of Physiology

Volumn 65, Issue , 2003, Pages 45-79

  Frey, N ^a,b   Olson, E N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cardiomyocyte; Heart failure; Signaling; Treatment

Indexed keywords

CALCINEURIN; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE; GLYCOPROTEIN GP 130; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; SODIUM PROTON EXCHANGE PROTEIN; STAT3 PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR;

CELL ACTIVITY; ENZYME ACTIVITY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; LIPID METABOLISM; MALADJUSTMENT; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SARCOMERE; SIGNAL TRANSDUCTION; ADAPTATION; ANIMAL; CARDIOMEGALY; HEART; HEART MUSCLE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CARDIOMEGALY; HEART; HUMANS; MYOCARDIUM;

EID: 0002537440     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.65.092101.142243     Document Type: Review

References (225)

1. Kannel WB, Gordon T, Offutt D. 1969. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann. Intern. Med. 71:89-105
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. 1990. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322:1561-66
3. Vakili BA, Okin PM, Devereux RB. 2001. Prognostic implications of left ventricular hypertrophy. Am. Heart J. 141:334-41
4. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, et al. 2001. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104:1615-21
5. Chien KR. 1999. Stress pathways and heart failure. Cell 98:555-58
6. MacLellan WR, Schneider MD. 2000. Genetic dissection of cardiac growth control pathways. Annu. Rev. Physiol. 62:289-319
7. Molkentin JD, Dorn GW II. 2001. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63:391-426
8. Olson EN, Williams RS. 2000. Calcineurin signaling and muscle remodeling. Cell 101:689-92
9. Crabtree GR, Olson EN. 2002. NFAT signaling: choreographing the social lives of cells. Cell 109(Suppl.):S67-79
10. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, et al. 1998. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215-28
11. Molkentin JD. 2000. Calcineurin and beyond: cardiac hypertrophic signaling. Circ. Res. 87:731-38
12. Leinwand LA. 2001. Calcineurin inhibition and cardiac hypertrophy: a matter of balance. Proc. Natl. Acad. Sci. USA 98:2947-49
13. Coghlan VM, Perrino BA, Howard M, Langeberg LK, Hicks JB, et al. 1995. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. Science 267:108-11
14. Taigen T, De Windt LJ, Lim HW, Molkentin JD. 2000. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. USA 97:1196-201
15. Lai MM, Burnett PE, Wolosker H, Blackshaw S, Snyder SH. 1998. Cain, a novel physiologic protein inhibitor of calcineurin. J. Biol. Chem. 273:18325-31
16. Sun L, Youn HD, Loh C, Stolow M, He W, Liu JO. 1998. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. Immunity 8:703-11
17. De Windt LJ, Lim HW, Bueno OF, Liang Q, Delling U, et al. 2001. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 98:3322-27
18. Fuentes JJ, Pritchard MA, Planas AM, Bosch A, Ferrer I, Estivill X. 1995. A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Hum. Mol. Genet. 4:1935-44
19. Rothermel B, Vega RB, Yang J, Wu H, Bassel-Duby R, Williams RS. 2000. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J. Biol. Chem. 275:8719-25
20. Kingsbury TJ, Cunningham KW. 2000. A conserved family of calcineurin regulators. Genes Dev. 14(13):1595-604
21. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, et al. 2000. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ. Res. 87:E61-68
22. Vega RB, Yang J, Rothermel BA, Bassel-Duby R, Williams RS. 2002. Multiple domains of MCIP1 contribute to inhibition of calcineurin activity. J. Biol. Chem. 277: 30401-7
23. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, et al. 2001. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 98:3328-33
24. Hill JA, Rothermel B, Yoo KD, Cabuay B, Demetroulis E, et al. 2002. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J. Biol. Chem. 277: 10251-55
25. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, et al. 2000. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101:2863-69
26. Shimoyama M, Hayashi D, Takimoto E, Zou Y, Oka T, et al. 1999. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 100:2449-54
27. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, et al. 1999. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ. Res. 84:735-40
28. Zou Y, Hiroi Y, Uozumi H, Takimoto E, Toko H, et al. 2001. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 104:97-101
29. Bueno OF, Wilkins BJ, Tymitz KM, Glascock BJ, Kimball TF, et al. 2002. Impaired cardiac hypertrophic response in calcineurin α-β-deficient mice. Proc. Natl. Acad. Sci. USA 99:4586-91
30. 2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J. Biol. Chem. 275(18):13571-79
31. Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IG, et al. 2000. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J. Clin. Invest. 106(11):1351-59
32. Frey N, Olson EN. 2000. Making matters worse for a broken heart. J. Clin. Invest. 106:1437-39
33. Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, et al. 2002. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J. Clin. Invest. 109:1013-20
34. Frey N, Richardson JA, Olson EN. 2000. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc. Natl. Acad. Sci. USA 97:14632-37
35. Frey N, Olson EN. 2002. Calsarcin-3, a novel skeletal muscle-specific member of the calsarcin family, interacts with multiple Z-disc proteins. J. Biol. Chem. 277:13998-4004
36. Cantley LC. 2002. The phosphoinositide 3-kinase pathway. Science 296:1655-57
37. Schluter KD, Goldberg Y, Taimor G, Schafer M, Piper HM. 1998. Role of phosphatidylinositol 3-kinase activation in the hypertrophic growth of adult ventricular cardiomyocytes. Cardiovasc. Res. 40:174-81
38. Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, et al. 2000. The beta(2)-adrenergic receptor delivers an anti-apoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase. Circ. Res. 87: 1172-79
39. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP. 2001. Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc. Natl. Acad. Sci. USA 98:1601-12
40. Leevers SJ, Weinkove D, MacDougall LK, Hafen E, Waterfield MD. 1996. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. 15:6584-94
41. Naga Prasad SV, Esposito G, Mao L, Koch WJ, Rockman HA. 2000. Gβγ-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J. Biol. Chem. 2757:4693-98
42. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, et al. 2000. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19:2537-48
43. Alessi DR, James SR, Downes CP, Hohnes AB, Gaffney PR, et al. 1997. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr. Biol. 7:261-69
44. Rintelen F, Stocker H, Thomas G, Hafen E. 2001. PDK1 regulates growth through Akt and S6K in Drosophila. Proc. Natl. Acad. Sci. USA 98:15020-25
45. Verdu J, Buratovich MA, Wilder EL, Birnbaum MJ. 1999. Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat. Cell Biol. 1:500-6
46. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, et al. 2002. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22:2799-809
47. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, et al. 2002. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 277:22896-901
48. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, et al. 2001. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3:1014-19
49. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. 2002. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16:1472-87
50. Tu VC, Bahl JJ, Chen QM. 2002. Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. J. Pharmacol. Exp. Ther. 300:1101-10
51. Boluyt MO, Zheng JS, Younes A, Long X, O'Neill L, et al. 1997. Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. Circ. Res. 81:176-86
52. Sadoshima J, Izumo S. 1995. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ. Res. 77:1040-52
53. Ono Y, Ito H, Tamamori M, Nozato T, Adachi S, et al. 2000. Role and relation of p70 S6 and extracellular signal-regulated kinases in the phenotypic changes of hypertrophy of cardiac myocytes. Jpn. Circ. J. 64:695-700
54. Zhou P, Sun LJ, Dotsch V, Wagner G, Verdine GL. 1998. Solution structure of the core NFATC1/DNA complex. Cell 92:687-96
55. Dufner A, Andjelkovic M, Burgering BM, Hemmings BA, Thomas G. 1999. Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol. Cell. Biol. 9:4525-34
56. Morisco C, Zebrowski D, Condorelli G, Tsichlis P, Vatner SF, Sadoshima J. 2000. The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes. J. Biol. Chem. 275:14466-75
57. Haq S, Choukroun G, Kang ZB, Ranu H, Matsui T, et al. 2000. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 151:117-30
58. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, et al. 2002. Activated glycogen synthase kinase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 99:907-12
59. Badorff C, Ruetten H, Mueller S, Stahmer M, Gehring D, et al. 2002. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J. Clin. Invest. 109:373-81
60. Hardt SE, Sadoshima J. 2002. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ. Res. 90:1055-63
61. Boyle WJ, Smeal T, Defize LH, Angel P, Woodgett JR, et al. 1991. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 64:573-84
62. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. 2000. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14:2501-14
63. Ginger RS, Dalton EC, Ryves WJ, Fukuzawa M, Williams JG, Harwood AJ. 2000. Glycogen synthase kinase-3 enhances nuclear export of a Dictyostelium STAT protein. EMBO J. 19:5483-91
64. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. 2000. Requirement for glycogen synthase kinase-3 beta in cell survival and NF-kappaB activation. Nature 406:86-90
65. Molkentin JD, Lin Q, Duncan SA, Olson EN. 1997. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev. 11:1061-72
66. Liang Q, De Windt LJ, Wirt SA, Kimball TR, Markham BE, Molkentin JD. 2001. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J. Biol. Chem. 276:30245-53
67. Morisco C, Seta K, Hardt SE, Lee Y, Vatner SF, Sadoshima J. 2001. Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J. Biol. Chem. 276: 28586-97
68. Cohen P, Frame S. 2001. The renaissance of GSK3. Nat. Rev. Mol. Cell. Biol. 2:769-76
69. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. 1998. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest. 101: 812-18
70. Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, et al. 1995. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378:65-68
71. Oliver PM, John SW, Purdy KE, Kim R, Maeda N, et al. 1998. Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-dependent manner. Proc. Natl. Acad. Sci. USA 95:2547-51
72. Kuhn M, Holtwick R, Baba HA, Perriard JC, Schmitz W, Ehler E. 2002. Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice. Heart 87:368-74
73. Kishimoto I, Rossi K, Garbers DL. 2001. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl. Acad. Sci. USA 98:2703-6
74. Frey N, McKinsey TA, Olson EN. 2000. Decoding calcium signals involved in cardiac growth and function. Nat. Med. 6:1221-27
75. McKinsey TA, Olson EN. 1999. Cardiac hypertrophy: sorting out the circuitry. Curr. Opin. Genet. Dev. 9(3):267-74
76. Houser SR, Piacentino V 3rd, Weisser J. 2000. Abnormalities of calcium cycling in the hypertrophied and failing heart. J. Mol. Cell. Cardiol. 32:1595-607
77. McKinsey TA, Zhang CL, Olson EN. 2002. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 27:40-47
78. Naya FJ, Wu C, Richardson JA, Overbeek P, Olson EN. 1999. Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. Development 126:2045-52
79. Passier R, Zeng H, Frey N, Naya FJ, Nicol RL, et al. 2000. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 105:1395-406
80. McKinsey TA, Zhang CL, Olson EN. 2001. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Mol. Cell. Biol. 21:6312-21
81. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. 2002. Class II histone deacytelases act as signal-responsive repressors of cardiac hypertrophy. Cell 110:479-88
82. 2+/calmodulin- dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J. Biol. Chem. 277:1261-67
83. Colomer JM, Means AR. 2000. Chronic elevation of calmodulin in the ventricles of transgenic mice increases the autonomous activity of calmodulin-dependent protein kinase II, which regulates atrial natriuretic factor gene expression. Mol. Endocrinol. 14:1125-36
84. Rockman HA, Koch WJ, Lefkowitz RJ. 2002. Seven-transmembrane-spanning receptors and heart function. Nature 415: 206-12
85. Nicol RL, Frey N, Olson EN. 2000. From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease. Annu. Rev. Genomics Hum. Genet. 1:179-223
86. Koch WJ, Lefkowitz RJ, Rockman HA. 2000. Functional consequences of altering myocardial adrenergic receptor signaling. Annu. Rev. Physiol. 62:237-60
87. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. 2000. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc. Natl. Acad. Sci. USA 97:931-36
88. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, et al. 1997. Transgenic G alpha q overexpression induces cardiac contractile failure in mice. Proc. Natl. Acad. Sci. USA 94:8121-26
89. Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn GW II. 1998. Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation 97(15):1488-95
90. Offermanns S, Zhao LP, Gohla A, Sarosi I, Simon MI, Wilkie TM. 1998. Embryonic cardiomyocyte hypoplasia and craniofacial defects in G alpha q/G alpha 11-mutant mice. EMBO J. 17:4304-12
91. Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie TM, et al. 2001. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat. Med. 7:1236-40
92. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. 1998. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280:574-77
93. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, et al. 2002. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105:85-92
94. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:145-53
95. Daaka Y, Luttrell LM, Lefkowitz RJ. 1997. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390:88-91
96. Engelhardt S, Hein L, Keller U, Klambt K, Lohse MJ. 2002. Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ. Res. 90:814-19
97. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, et al. 2000. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J. Mol. Cell. Cardiol. 32:817-30
98. Gaudin C, Ishikawa Y, Wight DC, Mahdavi V, Nadal-Ginard B, et al. 1995. Overexpression of Gs alpha protein in the hearts of transgenic mice. J. Clin. Invest. 95:1676-83
99. Roth DM, Gao MH, Lai NC, Drumm J, Dalton N, et al. 1999. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 99:3099-3102
100. Roth DM, Bayat H, Drumm JD, Gao MH, Swaney JS, et al. 2002. Adenylyl cyclase increases survival in cardiomyopathy. Circulation 105:1989-94
101. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, et al. 2001. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ. Res. 89:997-1004
102. Dorn GW II, Tepe NM, Lorenz JN, Koch WJ, Liggett SB. 1999. Low-and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc. Natl. Acad. Sci. USA 96:6400-5
103. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, et al. 1982. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. 307(4):205-11
104. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, et al. 1998. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc. Natl. Acad. Sci. USA 95:7000-5
105. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA. 2001. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc. Natl. Acad. Sci. USA 98:5809-14
106. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, et al. 1996. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334:1349-55
107. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). 1999. Lancet 353:2001-7
108. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. 1999. Lancet 353:9-13
109. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, et al. 2002. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N. Engl. J. Med. 346:1357-65
110. Neumann J, Schmitz W, Scholz H, von Meyerinck L, Doring V, Kalmar P. 1988. Increase in myocardial Gi-proteins in heart failure. Lancet 2:936-37
111. Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, et al. 1992. Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure. Circ. Res. 70:688-96
112. Bohm M, Gierschik P, Knorr A, Schmidt U, Weismann K, Erdmann E. 1993. Cardiac adenylyl cyclase, beta-adrenergic receptors, and G proteins in salt-sensitive hypertension. Hypertension 22:715-27
113. Redfern CH, Degtyarev MY, Kwa AT, Salomonis N, Cotte N, et al. 2000. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc. Natl. Acad. Sci USA 97:4826-31
114. Clerk A, Sugden PH. 2000. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ. Res. 86: 1019-23
115. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. 1995. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J. Biol. Chem. 270:23173-78
116. Fuller SJ, Gillespie-Brown J, Sugden PH. 1998. Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J. Biol. Chem. 273:18146-52
117. Thorburn A. 1994. Ras activity is required for phenylephrine-induced activation of mitogen-activated protein kinase in cardiac muscle cells. Biochem. Biophys. Res. Commun. 205:1417-22
118. Abdellatif M, Packer SE, Michael LH, Zhang D, Charng MJ, Schneider MD. 1998. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: implications for cardiac hypertrophy. Mol. Cell. Biol. 18:6729-36
119. Ichida M, Finkel T. 2001. Ras regulates NFAT3 activity in cardiac myocytes. J. Biol. Chem. 276:3524-30
120. Hall A. 1998. Rho GTPases and the actin cytoskeleton. Science 279:509-14
121. Hoshijima M, Sah VP, Wang Y, Chien KR, Brown JH. 1998. The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J. Biol. Chem. 273(13):7725-30
122. Aoki H, Sadoshima J, Izumo S. 2000. Myosin light chain kinase mediates sarcomere organization during cardiac hypertrophy in vitro. Nat. Med. 6:183-88
123. Sah VP, Hoshijima M, Chien KR, Brown JH. 1996. Rho is required for Gαq-and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J. Biol. Chem. 271:31185-90
124. Hines WA, Thorburn A. 1998. Ras and rho are required for Gαq-induced hypertrophic gene expression in neonatal rat cardiac myocytes. J. Mol. Cell. Cardiol. 30:485-94
125. Kuwahara K, Saito Y, Nakagawa O, Kishimoto I, Harada M, et al. 1999. The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes-possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett. 452:314-18
126. Sah VP, Minamisawa S, Tam SP, Wu TH, Dorn GW II, et al. 1999. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J. Clin. Invest. 103:1627-34
127. Sotiropoulos A, Gineitis D, Copeland J, Treisman R. 1999. Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. Cell 98:159-69
128. Zhang X, Azhar G, Chai J, Sheridan P, Nagano K, et al. 2001. Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. Am. J. Physiol. Heart Circ. Physiol. 280: H1782-H92
129. Arai A, Spencer JA, Olson EN. 2002. STARS, a striated muscle activator of Rho signaling and serum response factor-dependent transcription. J. Biol. Chem. 277:24453-59
130. Yanazume T, Hasegawa K, Wada H, Morimoto T, Abe M, et al. 2002. Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy. J. Biol. Chem. 277:8618-25
131. Pracyk JB, Tanaka K, Hegland DD, Kim KS, Sethi R, et al. 1998. A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J. Clin. Invest. 102:929-37
132. Sussman MA, Welch S, Walker A, Klevitsky R, Hewett TE, et al. 2000. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J. Clin. Invest. 105:875-86
133. Eble DM, Strait JB, Govindarajan G, Lou J, Byron KL, Samarel AM. 2000. Endothelin-induced cardiac myocyte hypertrophy: role for focal adhesion kinase. Am. J. Physiol. Heart Circ. Physiol. 278:H1695-H707
134. Taylor JM, Rovin JD, Parsons JT. 2000. A role for focal adhesion kinase in phenylephrine-induced hypertrophy of rat ventricular cardiomyocytes. J. Biol. Chem. 275:19250-57
135. Wu G, Yussman MG, Barrett TJ, Hahn HS, Osinska H, et al. 2001. Increased myocardial Rab GTPase expression: a consequence and cause of cardiomyopathy. Circ. Res. 89:1130-37
136. Sugden PH, Clerk A. 1998. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ. Res. 83:345-52
137. Bueno OF, DeWindt LJ, Lim HW, Tymitz KM, Witt SA, et al. 2001. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ. Res. 88:88-96
138. Pellieux C, Foletti A, Peduto G, Aubert JF, Nussberger J, et al. 2001. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J. Clin. Invest. 108:1843-51
139. Clerk A, Michael A, Sugden PH. 1998. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J. Cell Biol. 142:523-35
140. Glennon PE, Kaddoura S, Sale EM, Sale GJ, Fuller SJ, Sugden PH. 1996. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ. Res. 78:954-61
141. Post GR, Goldstein D, Thuerauf DJ, Glembotski CC, Brown JH. 1996. Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes. J. Biol. Chem. 271: 8452-57
142. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, et al. 2000. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19:6341-50
143. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. 2001. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 20:2757-67
144. Komuro I, Kudo S, Yamazaki T, Zou Y, Shiojima I, Yazaki Y 1996. Mechanical stretch activates the stress-activated protein kinases in cardiac myocytes. FASEB J. 10:631-36
145. Choukroun G, Hajjar R, Kyriakis JM, Bonventre JV, Rosenzweig A, Force T. 1998. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J. Clin. Invest. 102:1311-20
146. 2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes. J. Biol. Chem. 272:31203-8
147. Yano M, Kim S, Izumi Y, Yamanaka S, Iwao H. 1998. Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ. Res. 83:752-60
148. 2-terminal kinase in ventricular muscle cells. J. Biol. Chem. 273:5423-26
149. Choukroun G, Hajjar R, Fry S, del Monte F, Haq S, et al. 1999. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J. Clin. Invest. 104:391-98
150. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, et al. 1996. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ. Res. 79:162-73
151. Minamino T, Yujiri T, Terada N, Taffet GE, Michael LH, et al. 2002. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc. Natl. Acad. Sci. USA 99:3866-71
152. Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, et al. 2002. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J. Clin. Invest. 110:271-79
153. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, et al. 1998, Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem. 273:2161-68
154. Takeishi Y, Huang Q, Abe J, Glassman M, Che W, et al. 2001. Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch. J. Mol. Cell. Cardiol. 33:1637-48
155. Ueyama T, Kawashima S, Sakoda T, Rikitake Y, Ishida T, et al. 1999. Endothelin-1 activates p38 mitogen-activated protein kinase via endothelin-A receptor in rat myocardial cells. Mol. Cell. Biochem. 199:119-24
156. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, et al. 2000. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. 6:556-63
157. Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ. 1997. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386:296-99
158. Yang TT, Xiong Q, Enslen H, Davis RJ, Chow CW. 2002. Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol. Cell. Biol. 22:3892-904
159. Henrich CJ, Simpson PC. 1988. Differential acute and chronic response of protein kinase C in cultured neonatal rat heart myocytes to alpha 1-adrenergic and phorbol ester stimulation. J. Mol. Cell. Cardiol. 20:1081-85
160. Bowman JC, Steinberg SF, Jiang TR, Geenen DL, Fishman GI, Buttrick PM. 1997. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J. Clin. Invest. 100:2189-95
161. Huang L, Wolska BM, Montgomery DE, Burkart EM, Buttrick PM, Solaro RJ. 2001. Increased contractility and altered Ca(2+) transients of mouse heart myocytes conditionally expressing PKC-beta. Am. J. Physiol. Cell Physiol. 280: C1114-C20
162. Tian R, Miao W, Spindler M, Javadpour MM, McKinney R, et al. 1999. Long-term expression of protein kinase C in adult mouse hearts improves postischemic recovery. Proc. Natl. Acad. Sci. USA 96:13536-41
163. Roman BB, Geenen DL, Leitges M, Buttrick PM. 2001. PKC-beta is not necessary for cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 280:H2264-H70
164. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA. 2000. Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ. Res. 86:1218-23
165. Pass JM, Zheng Y, Wead WB, Zhang J, Li RC, et al. 2001. PKCepsilon activation induces dichotomous cardiac phenotypes and modulates PKCepsilon-RACK interactions and RACK expression. Am. J. Physiol. Heart Circ. Physiol. 280:H946-H55
166. Braz JC, Bueno OF, De Windt LJ, Molkentin JD. 2002. PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signalregulated kinase1/2 (ERK1/2). J. Cell Biol. 156:905-19
167. Schechtman D, Mochly-Rosen D. 2001. Adaptor proteins in protein kinase C-mediated signal transduction. Oncogene 20:6339-47
168. Pennica D, Shaw KJ, Swanson TA, Moore MW, Shelton DL, et al. 1995. Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J. Biol. Chem. 270:10915-22
169. Sano M, Fukuda K, Kodama H, Pan J, Saito M, et al. 2000. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J. Biol. Chem. 275:29717-23
170. Hirota H, Yoshida K, Kishimoto T, Taga T. 1995. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl. Acad. Sci. USA 92:4862-66
171. Hoshijima M, Chien KR. 2002. Mixed signals in heart failure: cancer rules. J. Clin. Invest. 109:849-55
172. Yamauchi-Takihara K, Kishimoto T. 2000. A novel role for STAT3 in cardiac remodeling. Trends Cardiovasc. Med. 10: 298-303
173. Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K, Kishimoto T. 1998. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98:346-52
174. Kunisada K, Negoro S, Tone E, Funamoto M, Osugi T, et al. 2000. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl. Acad. Sci. USA 97: 315-19
175. Uozumi H, Hiroi Y, Zou Y, Takimoto E, Toko H, et al. 2001. gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J. Biol. Chem. 276:23115-19
176. Yasukawa H, Hoshijima M, Gu Y, Nakamura T, Pradervand S, et al. 2001. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J. Clin. Invest. 108:1459-67
177. Banerjee A, Banks AS, Nawijn MC, Chen XP, Rothman PB. 2002. Cutting edge: Suppressor of cytokine signaling 3 inhibits activation of NFATp. J. Immunol. 168:4277-81
178. Hirota H, Chen J, Betz UAK, Rajewsky K, Gu Y, et al. 1999. Loss of gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97:189-98
179. Depre C, Shipley GL, Chen W, Han Q, Doenst T, et al. 1998. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat. Med. 4:1269-75
180. Barger PM, Kelly DP. 2000. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10(6):238-45
181. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. 1998. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83:1097-103
182. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, et al. 1999. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4:585-95
183. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, et al. 2002. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240-46
184. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. 2001. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104:1670-75
185. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. 2000. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin. Invest. 105: 1723-30
186. Jamshidi Y, Montgomery HE, Hense HW, Myerson SG, Torra IP, et al. 2002. Peroxisome proliferator-activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation 105:950-95
187. Young ME, Laws FA, Goodwin GW, Taegtmeyer H. 2001. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem. 276:44390-95
188. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, et al. 2002. The cardiac phenotype induced by PPAR alpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109:121-30
189. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, Lin A. 2001. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. USA 98:6668-73
190. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, et al. 1999. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 85(5):394-402
191. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, et al. 2000. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ. Res. 87:596-602
192. Li M, Pascual G, Glass CK. 2000. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20(13):4699-707
193. Zhou MD, Sucov HM, Evans RM, Chien KR. 1995. Retinoid-dependent pathways suppress myocardial cell hypertrophy. Proc. Natl. Acad. Sci. USA 92:7391-95
194. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, et al. 2000. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J. Biol. Chem. 275: 4541-44
195. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X. 1999. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin. Exp. Pharmacol. Physiol. 26:903-8
196. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, et al. 2001. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor. Circulation 104:576-81
197. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, et al. 2002. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105:868-73
198. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, et al. 2001. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104:317-24
199. Oi S, Haneda T, Osaki J, Kashiwagi Y, Nakamura Y, et al. 1999. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur. J. Pharmacol. 376:139-48
200. Luo JD, Xie F, Zhang WW, Ma XD, Guan JX, Chen X. 2001. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br. J. Pharmacol. 132:159-64
201. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, et al. 2001. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108:1429-37
202. Laufs U, Kilter H, Konkol C, Wassmann S, Bohm M, Nickenig G. 2002. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc. Res. 53:911-20
203. Lee RT. 2001. Matrix metalloproteinase inhibition and the prevention of heart failure. Trends Cardiovasc. Med. 11:202-5
204. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, et al. 2000. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102:1944-49
205. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, et al. 1999. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99:3063-70
206. Chancey AL, Brower GL, Peterson JT, Janicki JS. 2002. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105:1983-88
207. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, et al. 2002. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 8:35-40
208. Liu ZP, Nakagawa O, Nakagawa M, Yanagisawa H, Passier R, et al. 2001. CHAMP, a novel cardiac-specific helicase regulated by MEF2C. Dev. Biol. 234:497-509
209. Liu ZP, Olson EN. 2002. Suppression of proliferation and cardiomyocyte hypertrophy by CHAMP, a cardiac-specific RNA helicase. Proc. Natl. Acad. Sci. USA 99:2043-48
210. Ikeda MA, Jakoi L, Nevins JR. 1996. A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc. Natl. Acad. Sci. USA 93:3215-20
211. Takewaki S, Kuro-o M, Hiroi Y, Yamazaki T, Noguchi T, et al. 1995. Activation of Na(+)-H+ antiporter (NHE-1) gene expression during growth, hypertrophy and proliferation of the rabbit cardiovascular system. J. Mol. Cell. Cardiol. 27:729-42
212. Yoshida H, Karmazyn M. 2000. Na(+)/ H(+) exchange inhibition attenuates hypertrophy and heart failure in 1-wk postinfarction rat myocardium. Am. J. Physiol. Heart Circ. Physiol. 278:H300-H4
213. Yamazaki T, Komuro I, Kudoh S, Zou Y, Nagai R, et al. 1998. Role of ion channels and exchangers in mechanical stretch-induced cardiomyocyte hypertrophy. Circ. Res. 82:430-37
214. Cingolani HE, de Hurtado MCC. 2002. Na(+)-H(+) exchanger inhibition: a new antihypertrophic tool. Circ. Res. 90:751-53
215. Kusumoto K, Haist JV, Karmazyn M. 2001. Na(+)/H(+) exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am. J. Physiol. Heart Circ. Physiol. 280:H738-H45
216. Engelhardt S, Hein L, Keller U, Klambt K, Lohse MJ. 2002. Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ. Res. 90:814-19
217. Medugorac I. 1980. Collagen content in different areas of normal and hypertrophied rat myocardium. Cardiovasc. Res. 14:551-54
218. Iemitsu M, Miyauchi T, Maeda S, Sakai S, Kobayashi T, et al. 2001. Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281:R2029-R36
219. Kinugawa K, Yonekura K, Ribeiro RC, Eto Y, Aoyagi T, et al. 2001. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ. Res. 89:591-98
220. Rogers JH, Tamirisa P, Kovacs A, Weinheimer C, Courtois M, et al. 1999. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J. Clin. Invest. 104:567-76
221. Frank K, Kranias EG. 2000. Phospholamban and cardiac contractility. Ann. Med. 32:572-78
222. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, et al. 2001. S100A1: a regulator of myocardial contractility. Proc. Natl. Acad. Sci. USA 98:13889-94
223. Du XJ, Cole TJ, Tenis N, Gao XM, Kontgen F, et al. 2002. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol. Cell. Biol. 22:2821-29
224. Bartunek J, Weinberg EO, Tajima M, Rohrbach S, Katz SE, et al. 2000. Chronic N(G)-nitro-L-arginine methyl ester-induced hypertension: novel molecular adaptation to systolic load in absence of hypertrophy. Circulation 101:423-29
225. Tsoporis JN, Marks A, Kahn HJ, Butany JW, Liu PP, et al. 1998. Inhibition of norepinephrine-induced cardiac hypertrophy in S100beta transgenic mice. J. Clin. Invest. 102:1609-16